Actym Therapeutics
Biotechnology company developing programmable bacteria-based therapeutics for systemic delivery of combination payloads directly to solid tumors.
Website
https://www.actymthera.comLocation
Berkeley, California, USA
Founded
2017
Investors
1
Categories
oncology, drug-delivery, immunotherapy, biotech, bacteria-therapeutics
Notes
Actym Therapeutics is a biotechnology company pioneering the use of engineered bacteria for cancer therapy. Their proprietary STACT (Systemically-administered Tumor-homing Actym Construct Technology) platform uses programmed bacteria to selectively colonize solid tumors and deliver therapeutic payloads directly to the tumor microenvironment.
The company's approach enables systemic delivery with tumor-specific effects, potentially overcoming limitations of traditional drug delivery methods for solid tumors.
Team
- David Oh - Co-founder & CEO
- LinkedIn: linkedin.com/in/davidoh
- David Bermudes, Ph.D. - Co-founder & Chief Scientific Officer
- Christopher Thanos, Ph.D. - Board Member (Polaris Partners)
Additional Research Findings
- STACT platform enables programmable, combination payload delivery
- Bacteria naturally colonize solid tumors when administered systemically
- Engineered bacteria can be programmed to express multiple therapeutic agents
- Focus on immunotherapy combinations for solid tumors
- Backed by Polaris Partners
- Based in Berkeley, California
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Illumina Ventures | San Francisco, California, USA | biotech-focused | seedseries-a+1 | 32 |